6533b871fe1ef96bd12d1114

RESEARCH PRODUCT

Biomarkers and clinical characteristics of autoimmune chronic spontaneous urticaria: Results of the PURIST Study.

Martin K. ChurchElias ToubiPetra StaubachGordon SussmanRiccardo AseroNadine MarroucheCarsten Bindslev-jensenClive GrattanArno KrommingaMarcus MaurerMarta FerrerPer Stahl SkovTamar KinaciyanAndré EllrichUlrike RaapAna Giménez-arnauNicole SchoepkeAlvaro DaschnerGeorge N. KonstantinouPeter Schmid-grendelmeierThilo JakobThilo JakobMichael MakrisEdward F. KnolKe Zhang

subject

0301 basic medicinechronic spontaneous urticariaMaleBasophilIgG autoantibodiesImmunoglobulin EAutoantigensHistamine Releasechemistry.chemical_compound0302 clinical medicineIron-Binding ProteinsImmunology and AllergyChronic UrticariaReceptorAutologous serum skin testbiologyDegranulationMiddle AgedChronic spontaneous urticariaAntibodies Anti-IdiotypicBasophilsmedicine.anatomical_structurePhenotypeAutologous serum skin testautologous serum skin testFemaleSymptom AssessmentHistamineAdultAdolescentImmunologyIodide PeroxidaseAutoimmune Diseases03 medical and health sciencesYoung Adultautoimmune CSUmedicineJournal ArticleHumansAgedAutoantibodiesbusiness.industryReceptors IgEAutoantibodyBasophil activation030104 developmental biology030228 respiratory systemchemistryImmunoglobulin GImmunologyBasophil activation assaysbiology.proteinAutoimmune CSUbusinessbasophil activation assaysBiomarkers

description

Background: Autoimmune chronic spontaneous urticaria (aiCSU) is an important subtype of chronic spontaneous urticaria (CSU) in which functional IgG autoantibodies to IgE or its high-affinity receptor (FcεRI) induces mast cell degranulation and subsequent symptom development. However, it has not been tightly characterized. This study aimed to better define the clinical and immunological features and to explore potential biomarkers of aiCSU. Methods: This was a multinational, multicenter study of 182 CSU patients. The clinical features studied included: urticaria activity and impact (UAS7 and quality of life); autologous serum skin test (ASST); IgG anti-FcεRI and IgG anti-IgE; IgG-anti-thyroperoxidase (IgG anti-TPO); total serum IgE; and basophil reactivity (BASO) using the basophil activation test (BAT) and basophil histamine release assay (BHRA). Results: Of the 182 patients, 107 (59%) were ASST+, 46 (25%) were BASO+, and 105 (58%) were IgG anti-FcεRI+/IgE+. Fifteen patients (8%) fulfilled all three criteria of aiCSU. aiCSU patients appeared more severe (UAS7 21 vs 9 P < 0.016) but showed no other clinical or demographic differences from non-aiCSU patients. aiCSU patients also had markedly lower total IgE levels (P < 0.0001) and higher IgG anti-TPO levels (P < 0.001). Of biomarkers, positive BAT and BHRA tests were 69% and 88% predictive of aiCSU, respectively. Conclusions: aiCSU is a relatively small but immunologically distinct subtype of CSU that cannot be identified by routine clinical parameters. Inclusion of BHRA or BAT in the diagnostic workup of CSU patients may aid identification of aiCSU patients, who may have a different prognosis and benefit from specific management.

10.1111/all.13949https://pubmed.ncbi.nlm.nih.gov/31228881